These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19290406)

  • 21. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia.
    Undas A; Stepień E; Glowacki R; Tisończyk J; Tracz W; Jakubowski H
    Thromb Haemost; 2006 Sep; 96(3):342-7. PubMed ID: 16953277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homocysteine, B vitamins, and cardiovascular disease.
    de Craen AJ; Stott DJ; Westendorp RG
    N Engl J Med; 2006 Jul; 355(2):205-6; author reply 209-11. PubMed ID: 16837687
    [No Abstract]   [Full Text] [Related]  

  • 23. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients.
    Alvares Delfino VD; de Andrade Vianna AC; Mocelin AJ; Barbosa DS; Mise RA; Matsuo T
    Nutrition; 2007 Mar; 23(3):242-7. PubMed ID: 17321110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance.
    Mudge DW; Rogers R; Hollett P; Law B; Reiger K; Petrie JJ; Price L; Johnson DW; Campbell SB; Isbel NM; Sullivan M; Hawley CM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2178-85. PubMed ID: 16030045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observational study on markers of cardiovascular risk in renal patient: conventional hemodialysis vs. haemofiltration online.
    Melero-Rubio E; Párraga-Díaz M; Gómez-Sánchez MP; Pellicer-Villaescusa S; Merchán-Mayado E
    J Ren Care; 2009 Dec; 35(4):201-4. PubMed ID: 19909413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hypeRhomocysteinemia: an epiDemiological study in Indians, additionally evaluating the effect of Oral VITamin supplementation).
    Shenoy KT; Lena KB; Sali N; Syam S; Shenoy ST; Rajadhyaksha VD; Pai GP; Shaikh AA;
    Curr Med Res Opin; 2006 Apr; 22(4):641-8. PubMed ID: 16684424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homocysteine and endothelial markers are increased in patients with chronic liver diseases.
    Remková A; Remko M
    Eur J Intern Med; 2009 Sep; 20(5):482-6. PubMed ID: 19712849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Folic acid reduces adhesion molecules VCAM-1 expession in aortic of rats with hyperhomocysteinemia.
    Li M; Chen J; Li YS; Feng YB; Gu X; Shi CZ
    Int J Cardiol; 2006 Jan; 106(2):285-8. PubMed ID: 16183151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients.
    Sombolos K; Fragia T; Natse T; Bartholomatos G; Karagianni A; Katsaris G; Christidou F; Bamichas G; Stangou M; Papagalanis N
    J Nephrol; 2002; 15(6):671-5. PubMed ID: 12495282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Homocysteine, folic acid, group B vitamins and cardiovascular risk].
    Blacher J; Czernichow S; Horrellou MH; Conad J; David P; Chadefaux-Vekemans B; Ankria A; Galan P; Hercberg S; Ducimetière P
    Arch Mal Coeur Vaiss; 2005 Feb; 98(2):145-52. PubMed ID: 15787307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folic acid supplementation inhibits NADPH oxidase-mediated superoxide anion production in the kidney.
    Hwang SY; Siow YL; Au-Yeung KK; House J; O K
    Am J Physiol Renal Physiol; 2011 Jan; 300(1):F189-98. PubMed ID: 20980407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins.
    Apeland T; Frøyland ES; Kristensen O; Strandjord RE; Mansoor MA
    Epilepsy Res; 2008 Nov; 82(1):1-6. PubMed ID: 18644700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperhomocysteinemia in children on renal replacement therapy.
    Feinstein S; Sela BA; Drukker A; Becker-Cohen R; Raveh D; Gavendo S; Frishberg Y
    Pediatr Nephrol; 2002 Jul; 17(7):515-9. PubMed ID: 12172765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The controversial role of B-vitamins in cardiovascular risk: An update.
    Ntaios G; Savopoulos C; Grekas D; Hatzitolios A
    Arch Cardiovasc Dis; 2009 Dec; 102(12):847-54. PubMed ID: 19963194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological dose of vitamin B12 is as effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients.
    Chiu YW; Chang JM; Hwang SJ; Tsai JC; Chen HC
    Ren Fail; 2009; 31(4):278-83. PubMed ID: 19462276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
    Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
    Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The C677T thermolabile variant of methylene tetrahydrofolate reductase on homocysteine, folate and vitamin B12 in a hemodialysis center.
    Trimarchi H; Genoud V; Schiel A; Castañon M; Freixas E; Diaz ML; Schropp J; Martino D; Pereyra H; Kordich L
    Medicina (B Aires); 2002; 62(2):149-53. PubMed ID: 12038037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperhomocysteinemia in chronic renal failure: alternative therapeutic strategies.
    Perna AF; Sepe I; Lanza D; Pollastro RM; De Santo NG; Ingrosso D
    J Ren Nutr; 2012 Jan; 22(1):191-4. PubMed ID: 22200441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced risk of thrombotic disease in patients with acquired vitamin B12 and/or folate deficiency: role of hyperhomocysteinemia.
    Remacha AF; Souto JC; Rámila E; Perea G; Sarda MP; Fontcuberta J
    Ann Hematol; 2002 Nov; 81(11):616-21. PubMed ID: 12454698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.
    Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ
    J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.